Mark Leuchtenberger

A veteran of the biopharmaceutical industry, since joining Chiasma in 2015, Leuchtenberger has steered the company’s commercialisation of octreotide capsules for the treatment of acromegaly.

A veteran of the biopharmaceutical industry, since joining Chiasma in 2015, Leuchtenberger has steered the company’s commercialisation of octreotide capsules for the treatment of acromegaly.